Phase 1a study in healthy volunteers will assess safety, pharmacokinetics and pathway engagement; Phase 1b study in patients with advanced solid tumors planned to begin in January 2027 CANTANHEDE, Portugal, November 5, 2026 — Mondego Bio today announced the initiation of a first-in-human Phase 1 clinical study of MB‑388, an oral dual PTPN2/PTPN1 inhibitor designed … Continue reading Mondego Bio Initiates First-in-Human Study of MB‑388, an Oral Dual PTPN2/PTPN1 Inhibitor Designed to Overcome Resistance to Cancer Immunotherapy
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed